Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coya TherapeuticsCOYA -3.10%49 1-Year ROIIC % is -48.44 as of Jun. 2026. GuruFocus rates COYA with a GF Score™ of 49/100 and a GF Value™ of $6.54 (Significantly Undervalued). Among 1,329 Biotechnology companies, Coya Therapeutics ranks worse than 64.41% on this metric.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Coya Therapeutics's 1-Year ROIIC % for the quarter that ended in Jun. 2026 was -48.44%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Coya Therapeutics's 1-Year ROIIC % or its related term are showing as below:
COYA's 1-Year ROIIC % is ranked worse than 64.41% of 1329
companies
in the Biotechnology industry
Industry Median: -6.91
vs COYA: -48.44
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Coya Therapeutics 1-Year ROIIC % Related Terms
Coya Therapeutics 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Coya Therapeutics's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COYA vs ONCY, GUTS, SEER: 1-Year ROIIC % Comparison
For the Biotechnology subindustry, Coya Therapeutics's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coya Therapeutics 1-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coya Therapeutics's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Coya Therapeutics's 1-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Coya Therapeutics (COYA) has a 1-Year ROIIC % of -48.44 as of Jun. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Coya Therapeutics and its competitors. According to the industry distribution chart, Coya Therapeutics ranks #856 out of 1329 companies in the Biotechnology industry, placing it in the top 64.4%.
Is Coya Therapeutics' 1-Year ROIIC % too high?
Coya Therapeutics' current 1-Year ROIIC % is -48.44. Based on the distribution chart, Coya Therapeutics ranks #856 out of 1329 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Coya Therapeutics has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coya Therapeutics' 1-Year ROIIC % compare to ONCY and GUTS?
According to the Biotechnology industry distribution chart, Coya Therapeutics ranks #856 out of 1329 companies for 1-Year ROIIC %. This places Coya Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Biotechnology company?
A good 1-Year ROIIC % depends on the Biotechnology industry context. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Coya Therapeutics and its competitors. Coya Therapeutics's current 1-Year ROIIC % is -48.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coya Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Coya Therapeutics (COYA) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.54, compared to a current price of $4.39 — trading 32.9% below its estimated fair value. The current 1-Year ROIIC % is -48.44. Coya Therapeutics' overall GF Score™ is 49/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Coya Therapeutics (COYA), the current 1-Year ROIIC % is -48.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coya Therapeutics (COYA) Overvalued in 2026?
Based on GuruFocus' analysis, Coya Therapeutics stock appears to be undervalued.
The current stock price of $4.39 is trading 32.9% below its estimated GF Value™ of $6.54.
GuruFocus considers Coya Therapeutics to be Significantly Undervalued.
Key valuation signals for COYA:
1-Year ROIIC %: -48.44
GF Value™: $6.54 vs. price of $4.39 (32.9% below fair value)
No single metric tells the full story. See the COYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
49GF Score
Get the complete analysis for COYA
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COYA has been successfully added to your 
